Updates are available Correction dated 2024-10-19
Click to view Correction: https://doi.org/10.1186/s13045-024-01620-y
-
Authors
Alcantara, Marion
Chevrier, Marion
Jardin, Fabrice
Schmitt, Anna
Houillier, Caroline
Oberic, Lucie
Chinot, Olivier
Morschhauser, Franck
Peyrade, Frédéric
Houot, Roch
Hoang-Xuan, Khê
Ghesquieres, Hervé
Soussain, Carole
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 6 September 2024
First Online: 19 September 2024
Change Date: 19 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13045-024-01620-y
Declarations
:
: The study was conducted in compliance with Good Clinical Practice, as defined by the International Conference on Harmonization and according to applicable regulatory requirements. The study protocol and all amendments were approved by the competent authority and independent ethics committee. All patients, or the persons on confidence in case the neurological status of the patient did not allow him to understand and/or to sign, provided written informed consent before enrollment.
: Not applicable.
: AM performed scientific and medical consulting for Novartis, Janssen, Kite/Gilead and MSD and received research grants from Mnemo Therapeutics. OL has received honoraria and travel fundings from Roche, Kite/Gilead, BMS, Janssen and AstraZeneca. HR has received honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche; and is a member on an entity’s Board of Directors or advisory committees of Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte and Miltenyi. SC received a research grant from AstraZeneca.
